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The ACC Meeting is slated for 24-27/3/2012 in Chicago 
 
The Athens Cardiology Update 2012 is slated for April 
5-7, 2012 
 
The HRS 33rd Meeting will be held in Boston, 9-12/5/12 
 
The ESC Congress will be held in Munich, 25-29/8/2012 
 
ALLHAT Trial: Once Heart Failure Develops in 
High-Risk Hypertensive Patients, Mortality is High  
At a mean follow-up of 8.9 years, of 1761 participants 
in the ALLHAT trial with incident heart failure (HF) in-
trial, 1348 (77%) died. Mortality rates were similar across 
treatment comparisons, with adjusted 10-year all-cause 
mortality rates per 100 persons of 83 for chlorthalidone, 
86 for amlodipine, and 87 for lisinopril. Mortality was 
similar for those with preserved (81%) and low ejection 
fraction (84%). Thus, once HF develops, risk of death is 
high and consistent across randomized treatment groups. 
Measures to prevent the development of HF, especially 
blood pressure control, must be a priority if mortality 
associated with the development of HF is to be addressed 
(Piller LB et al, Circulation 2011;124:1811-1818).  
 
Isolated Low HDL-Cholesterol is Associated with 
Increased Coronary Risk 
Data from 220 060 participants (87% Asian) in 37 
studies from the Asia-Pacific region indicated low HDL-
C (HDL <40 mg/dl in men and <50 mg/dl in women) 
among 33.1% of Asians vs 27.0% of non-Asians 
(P<0.001). The prevalence of low HDL-C in the absence 
of other lipid abnormalities (isolated low HDL-C) was 
higher in Asians compared with non-Asians: 22.4% vs 
14.5%, respectively (P<0.001). After 6.8 years, there 
were 574 coronary heart disease and 739 stroke events. 
There was an inverse relationship between low HDL-C 
with coronary heart disease in all individuals (hazard 
ratio, 1.57). In Asians, isolated low levels of HDL-C were 
as strongly associated with coronary heart disease risk as 
low levels of HDL-C combined with other lipid 
abnormalities (hazard ratio, 1.67 vs 1.63, respectively). 
There was no association between low HDL-C and stroke 
risk (Huxley RR et al, Circulation2011;124:2056-2064).  
 
Occluded Artery Trial (OAT) Extended Follow-up: 
No Reduction of Long-term Rates of Clinical Events 
After Routine PCI in Stable Patients  
 OAT randomized 2201 stable patients with infarct-
related artery total occlusion >24 hours (days 3–28) after 
myocardial infarction (MI), excluding patients with 
severe inducible ischemia, rest angina, class III-IV heart 
failure, and 3-vessel/left main disease. At extended 
follow-up (6-year median survivor follow-up; longest, 9 
years), rates of fatal and nonfatal MI, death, and class IV 
heart failure were similar for the PCI and medical therapy 
alone groups. The vast majority of patients at each 
follow-up visit did not report angina. There was less 
angina in the PCI group through early in follow-up; there 
was a trend toward less angina in the PCI group at 3 and 
5 years. The 7-year rate of PCI of the infarct-related 
artery during follow-up was 11.1% for the PCI group 
compared with 14.7% for the medical therapy alone 
group (hazard ratio, 0.79; P=0.06). The authors 
concluded that extended follow-up of the OAT cohort 
showed no reduction of long-term rates of clinical events 
after routine PCI in stable patients with a totally occluded 
infarct-related artery and without severe inducible 
ischemia in the subacute phase after MI (Hochman JS et 
al, Circulation 2011;124:2320-2328).  
 
No Mortality Advantage for Transfer for Primary 
PCI over Onsite Thrombolysis when Transfer Door-
to-needle Time Exceeds ~2 Hours 
Among ST-segment–elevation myocardial infarction 
(STEMI) patients enrolled in a registry within 12 hours of 
pain onset, 81% of transfer for PCI patients were matched 
(n=9506) to onsite thrombolysis patients (n=9506). In the 
matched cohort, PCI was performed with delays >90 
minutes in 68%. Multivariable analysis found no 
mortality advantage for transfer for PCI over onsite 
thrombolysis when transfer door-to-needle time exceeded 
~120 minutes. The authors concluded that PCI-related 
delays are extensive among patients transferred for PCI 
and are associated with poorer outcomes. No differential 
excess in mortality was seen with transfer for PCI 
compared with onsite thrombolysis even with long PCI-
related delays, but as transfer door-to-needle time times 
increase, the mortality advantage for PCI over onsite 
thrombolysis declines (Pinto DS et al, Circulation 
2011;124:2512-2521).  
 
ALPHEE Study: Celivarone was not Effective for the 
Prevention of ICD Interventions or Sudden Death 
Celivarone, a noniodinated benzofuran derivative is a 
multichannel blocker and like amiodarone and 
dronedarone, it has class I, II, III, and IV antiarrhythmic 
effects, but may have an improved side-effect profile, 
faster time to effect and elimination times, and a reduced 
potential for drug-drug interactions. Celivarone (50, 100, 
or 300 mg/d) was compared with placebo and amiodarone 
(200 mg/d after loading dose of 600 mg/d for 10 days) in 
486 patients with a left ventricular ejection fraction <40% 
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and at least 1 ICD intervention for ventricular tachycardia 
(VT) or ventricular fibrillation (VF) in the previous 
month or ICD implantation in the previous month for 
documented VT/VF. At a median treatment duration of 9 
months, the proportion of patients experiencing an 
appropriate ICD intervention or sudden death was 61.5% 
in the placebo group; 67.0%, 58.8%, and 54.9% in the 
celivarone 50-, 100-, and 300-mg groups, respectively; 
and 45.3% in the amiodarone group. None of the 
comparisons vs placebo were statistically significant. 
Thus, celivarone was ineffective, although it had an 
acceptable safety profile (Kowey PR et al, Circulation 
2011;124:2649-2660).  
 
ROCKET-AF: Patients with AF and Moderate Renal 
Insufficiency Receiving Rivaroxaban Have Higher 
Rates of Stroke and Bleeding  
In the ROCKET-AF study, 14 264 patients with AF 
were randomized to rivaroxaban 20 mg/day [15 mg/day if 
creatinine clearance (CrCl) 30–49 mL/min] or dose-
adjusted warfarin (target INR 2.0–3.0). Compared with 
patients with CrCl >50 mL/min (mean age 73 years), the 
2950 (21%) patients with CrCl 30–49 mL/min were older 
(79 years) and had higher event rates irrespective of study 
treatment. Among those with CrCl 30–49 mL/min, stroke 
or systemic embolism occurred in 2.32 per 100 patient-
years with rivaroxaban 15 mg/day vs. 2.77 per 100 
patient-years with warfarin [hazard ratio (HR) 0.84] in 
the per-protocol population. Intention-to-treat analysis 
yielded similar results (HR 0.86) to the per-protocol 
results. Rates of major and clinically relevant non-major 
bleeding (17.82 vs. 18.28 per 100 patient-years; P= NS) 
and intracranial bleeding (0.71 vs. 0.88 per 100 patient-
years; P =NS) were similar with rivaroxaban or warfarin. 
Fatal bleeding (0.28 vs. 0.74% per 100 patient-years; P = 
0.047) occurred less often with rivaroxaban (Fox KAA et 
al, Eur Heart J 2011; 32: 2387–2394).  
 
GREATER-EARTH STUDY: Left ventricular (LV) 
Pacing is not Superior to Biventricular (BiV) Pacing, 
but Nonresponders to BiV Pacing May Respond 
Favorably to LV Pacing 
The effects of LV and biventricular (BiV) pacing on 
exercise tolerance and LV remodeling were compared in 
121 patients with an LV ejection fraction <35%, QRS 
>120 ms, and symptoms of heart failure. Exercise 
duration at 75% of peak VO2 (primary outcome) 
increased from 9.3+6.4 to 14.0+11.9 and 14.3+12.5 min 
with LV and BiV pacing, respectively, with no difference 
between groups (P=NS). LV ejection fraction improved 
from 24+6% to 32+11% and 31+10% with LV and BiV 
pacing, respectively, with no difference between groups 
(P=NS). Reductions in LV end-systolic volume were also 
similar (P=NS). The percentage of clinical responders 
(>20% increase in exercise duration) to LV and BiV 
pacing was 48.0% and 55.1% (P=NS). Positive 
remodeling responses (>15% reduction in LV end-
systolic volume) were noted in 46.7% and 55.4% 
(P=0.0881). Overall, ~31% of LV nonresponders 
improved with BiV and 17% of BiV nonresponders 
improved with LV pacing (Thibault B et al, Circulation 
2011; 124:2874-2881).  
 
TREAT Study: Darbepoetin Alfa Increases Strokes in 
Patients With Type 2 Diabetes Mellitus, Chronic 
Kidney Disease, and Anemia 
In 4038 patients with diabetes mellitus, chronic kidney 
disease, and anemia, randomized to receive darbepoetin 
alfa or placebo, the risk of stroke was doubled with 
darbepoetin alfa: 154 patients had a stroke, 101/2012 
(5.0%) in the darbepoetin alfa arm and 53/2026 (2.6%) in 
the placebo arm (hazard ratio 1.9). Independent predictors 
of stroke included assignment to darbepoetin alfa (odds 
ratio 2.1), history of stroke (odds ratio 2.0), more 
proteinuria, and known cardiovascular disease. In patients 
assigned to darbepoetin alfa, postrandomization systolic 
and diastolic blood pressure, hemoglobin level, platelet 
count, and darbepoetin alfa dose did not differ between 
those with and without stroke. Thus, the authors 
concluded that the 2-fold increase in stroke with 
darbepoetin alfa in TREAT could not be attributed to any 
baseline characteristic or to postrandomization blood 
pressure, hemoglobin, platelet count, or dose of 
treatment. These readily identifiable factors could not be 
used to mitigate the risk of darbepoetin alfa–related 
stroke (Skali H et al, Circulation 2011;124:2903-2908).  
 
2-Year Results of the PACE Trial: Biventricular (Biv) 
Pacing is Superior to Right Ventricular Apical (RVA) 
Pacing in Bradycardia Patients with Preserved 
Systolic Function 
Patients (n = 177) with bradycardia and preserved left 
ventricular (LV) ejection fraction (EF ≥45%) were 
randomized to receive RVA or BiV pacing. In the RVA 
pacing group (81 patients completing 2-year follow-up), 
LVEF further decreased from the first to the second year, 
but it remained unchanged in the BiV pacing group 
(n=82), leading to a significant difference of 9.9 % points 
between groups at 2-year follow-up (P < 0.001). 
Similarly, LV end-systolic volume (ESV) continued to 
enlarge from the first to the second year in the RVA 
pacing group (a difference of 13.0 mL; P < 0.001). 
Eighteen patients in the BiV pacing group (20.2%) and 55 
in the RVA pacing group (62.5%) had a significant 
reduction of LVEF (of ≥5%, P < 0.001). Thus, the authors 
concluded that LV adverse remodelling and deterioration 
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of systolic function continues at the second year after 
RVA pacing. This deterioration is prevented by BiV 
pacing (Chan JY et al, Eur Heart J 2011; 32:2533-2540).  
 
Everolimus Eluting Stents (EES) are Associated with 
Significant Reductions in Stent Thrombosis, Target 
Vessel Revascularization (TVR) and Myocardial 
Infarction (MI) compared to non–Everolimus-Eluting 
Drug Eluting Stents (DES) 
A total of 13 randomized trials (n = 17,101) were 
identified with a 22-month mean follow-up. Compared 
with non–everolimus eluting DES, the EES significantly 
reduced stent thrombosis (relative risk [RR]: 0.55; p = 
0.001), TVR (RR: 0.77; p = 0.004), and MI (RR: 0.78; p 
= 0.02). There was no difference in cardiac mortality 
between the groups (RR: 0.92; p = 0.38). The treatment 
effect was consistent by different follow-up times and 
duration of clopidogrel use. The treatment effects 
increased with higher baseline risks of the respective 
control groups with the strongest correlation observed for 
stent thrombosis (R2 = 0.89, p < 0.001) (Baber U et al, J 
Am Coll Cardiol 2011;58:1569–1577).  
 
HORIZONS-AMI Trial: Patients with In-hospital 
Major Bleeding (IHMB) after Primary PCI Have 
Increased 3-Year Rates of Morbidity and Mortality 
Primary PCI was performed in 3,345 (92.9%) of 3,602 
patients in the HORIZONS-AMI trial; in-hospital major 
bleeding (IHMB) developed in 231 (6.9%). At 3-year 
follow-up, patients with IHMB had higher mortality 
(24.6% vs. 5.4%, p < 0.0001) and major adverse 
cardiovascular events (40.3% vs. 20.5%, p < 0.0001). The 
harmful effect of major bleeding was observed within 1 
month, between 1 month and 1 year, and between 1 and 3 
years. IHMB was an independent predictor of mortality 
(hazard ratio: 2.80, p < 0.0001) at 3-year follow up. Thus, 
the authors concluded that patients with IHMB after 
primary PCI have significantly increased 3-year rates of 
morbidity and mortality. Further investigation is 
warranted to understand the mechanisms underlying this 
relationship and to further improve outcomes in patients 
with ST-segment myocardial infarction (Suh J et al, J Am 
Coll Cardiol 2011;58: 1750–1756). 
 
EPHESUS Substudy: Mineralocorticoid Receptor 
Antagonism Provides Cardiovascular Protection 
Beyond its Diuretic and Potassium-sparing Properties 
In the EPHESUS study, in which 6,080 patients with 
acute MI and heart failure with left ventricular 
dysfunction received eplerenone, a diuretic effect was 
indirectly estimated by changes at 1 month that was 
superior to the median changes in the placebo group in 
body weight (-0.05 kg) and in the estimated plasma 
volume reduction (+1.4%). In the eplerenone group, body 
weight (p < 0.0001) and plasma volume (p = 0.047) 
decreased, whereas blood protein and serum potassium 
increased (both, p < 0.0001), as compared with the 
placebo group, suggesting an eplerenone-induced diuretic 
effect, associated with a potassium-sparing effect. A 
diuretic effect, as an estimated plasma volume reduction, 
was independently associated with 11% to 19% better 
outcomes (lower all-cause death, cardiovascular death or 
cardiovascular hospitalization, all-cause death or 
hospitalization, hospitalization for heart failure). 
Potassium sparing was also independently associated with 
12% to 34% better outcomes. There was no significant 
interaction between the observed beneficial effects of 
eplerenone (9% to 17%) on cardiovascular outcomes and 
potassium-sparing or diuretic effects. Thus, the authors 
concluded that eplerenone’s beneficial effects on long-
term survival and cardiovascular outcomes were 
independent from early potassium-sparing or diuretic 
effects, suggesting that mineralocorticoid receptor 
antagonism provides cardiovascular protection beyond its 
diuretic and potassium-sparing properties (Rossignol P et 
al, J Am Coll Cardiol 2011;58:1958–66).  
 
U.K. TAVI Registry: Midterm to Long-term Survival 
after Transcatheter Aortic Valve Implantation 
(TAVI) is Encouraging, Although a Substantial 
Proportion of Patients Die Within the First Year 
Data were collected prospectively on 870 patients 
undergoing 877 TAVI procedures up until December 31, 
2009. Survival at 30 days was 92.9%, at 1 year 78.6% 
and at 2 years 73.7%. There was a marked attrition in 
survival between 30 days and 1 year. In a univariate 
model, survival was significantly adversely affected by 
renal dysfunction, the presence of coronary artery 
disease, and a nontransfemoral approach; whereas left 
ventricular function (ejection fraction <30%), the 
presence of moderate/severe aortic regurgitation, and 
chronic obstructive pulmonary disease remained the only 
independent predictors of mortality in the multivariate 
model. Thus, the authors concluded that midterm to long-
term survival after TAVI was encouraging, although a 
substantial proportion of patients died within the first year 
(Moat NE et al, J Am Coll Cardiol 2011;58:2130–8).  
 
“Real World” Adhoc PCI With Use of Sirolimus 
Eluting Stents (SES) and a Uniform Single-Operator 
Approach with 0.5 mm Stent Oversizing and High-
Pressure (>12-18 bar) Deployment Routinely 
Combined with Long-term Dual Antiplatelet Therapy 
Results in Excellent 1 & 2 Year Oucomes  
Among 260 patients receiving SES and/or other stents, 
3 groups were compared: 104 (40%) patients receiving 
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SES alone (Group A), 122 patients receiving SES plus 
other drug-eluting stents (DES) (Group B), and 34 
patients receiving SES plus bare metal stents (BMS) 
(Group C).The majority (93.8%) of PCI procedures were 
performed adhoc. Procedural success (99-100%) and 
residual stenosis (<0-10%) were similar among the 3 
groups. Multivessel PCI and stenting was performed in 
120 (46.3%) patients and multilesion PCI in the majority 
(89.2%) in this cohort. A median of 2 stents (mean of 
2.6±1.3 stents) were implanted. There was one 
occurrence of subacute stent thrombosis in group C 
(0.4%). All patients received combined therapy with 
aspirin and clopidogrel for >24 months. Over 16.3±14.7 
months of follow-up, survival free of events (death, MI, 
stroke, repeat revascularization and restenosis) was 
excellent at 98%, 96%, and 97% at 12 months and 95%, 
90% and 97% at 24 months for groups A, B and C 
respectively; p = 0.27. Clinical restenosis rates were low 
in all 3 groups (0% vs 1.6% vs 5.9%) (p=NS). Possible 
very late stent thrombosis could be suspected in 1 patient 
(group B). Thus, the authors concluded that in 260 
patients receiving SES and/or other stents, a uniform 
single-operator approach with 0.5 mm stent oversizing 
and high-pressure (>12-18 bar) deployment routinely 
combined with long-term dual antiplatelet therapy 
resulted in high procedural success (>99%), very low rate 
of subacute (0.4%) and late stent thrombosis (0.4%), very 
low clinical restenosis rates (0-5.9%) and overall 
excellent survival free of cardiovascular events at 1 and 2 
years (Manolis et al, Hosp Chronicles 2011; 6: 182-194).  
 
Correction of Mitral Regurgitation in Nonresponders 
to Cardiac Resynchronization Therapy by MitraClip 
Has a Beneficial Effect 
A total of 51 patients with severe symptoms not 
responding to cardiac resynchronization therapy (CRT) 
who also had significant functional mitral regurgitation 
(MR) (grade >2) underwent perutaneous MR correction 
with insertion of the MitraClip (MC). MC treatment was 
feasible in all patients (49% 1 clip, 46% 2 clips). There 
were 2 periprocedural deaths. Median follow-up was 14 
months. New York Heart Association functional class 
improved acutely upon discharge (73%) and continued to 
improve progressively during follow-up. The proportion 
of patients with significant residual MR (grade >2) 
progressively decreased during follow-up. Reverse LV 
remodeling and improved LVEF were detected at 6 
months, with further improvement at 12 months. Overall 
30-day mortality was 4.2%. Mortality during follow-up 
was 19.9 per 100 person-years. Nonsurvivors had more 
compromised clinical baseline conditions, longer QRS 
duration, and a more dilated heart. Thus, the authors 
concluded that functional MR treatment with the 
MitraClip in CRT nonresponders was feasible, safe, and 
demonstrated improved functional class, increased LVEF, 
and reduced LV volumes in about 70% of patients. 
(Auricchio A et al, J Am Coll Cardiol 2011;58:2183–
2189).  
 
PRELUDE Registry: VT/VF Inducibility is Unable to 
Identify High-risk Brugada Syndrome Patients 
The registry included 308 patients with a spontaneous 
or drug-induced Brugada type I ECG and without history 
of cardiac arrest. Programmed electrical stimulation was 
performed at enrollment and ventricular tachyarrhythmias 
were induced in 40% of patients.. During a median 
follow-up of 34 months, 14 arrhythmic events (4.5%) 
occurred: 13 appropriate shocks of the implantable 
defibrillator (ICD), and 1 cardiac arrest. Arrhythmia 
inducibility was not a predictor of events at follow-up (9 
of 14 events occurred in noninducible patients). History 
of syncope and spontaneous type I ECG (hazard ratio -
HR: 4.20), ventricular refractory period <200 ms (HR: 
3.91), and QRS fragmentation (HR: 4.94) were 
significant predictors of arrhythmias. Thus, the authors 
concluded that VT/VF inducibility was unable to identify 
high-risk patients, while the presence of a spontaneous 
type I ECG, history of syncope, ventricular effective 
refractory period <200 ms, and QRS fragmentation 
seemed useful to identify candidates for prophylactic ICD 
(Priori SG et al, J Am Coll Cardiol 2012;59:37–45).  
 
Important Review and Other Articles  
Mechanisms of coronary artery spasm (Lanza et al, 
Circulation 2011;124:1774-1782), Calcific aortic valve 
disease (Rajamannan et al, Circulation 2011;124:1783-
1791), Assessing adiposity (Cornier M-A et al, 
Circulation 2011; 124: 1996-2019), 2011 ACCF/AHA 
Focused Update of the Guideline for the management of 
patients with peripheral artery disease (Rooke TW et al, 
Circulation 2011; 2020-2045), Atrial fibrillation 
pathophysiology (Iwasaki Y et al, Circulation 2011; 124: 
2264-2274), 2011 ACCF/AHA/SCAI Guideline for PCI 
(Levine GN et al, Circulation 2011;124:e574-e651), 
2011 ACCF/AHA Guideline for Coronary Artery Bypass 
Graft Surgery (Hillis LD et al, Circulation 2011; 124: 
e652-e735), 2011 ACCF/AHA Guideline for the 
diagnosis & treatment of hypertrophic cardiomyopathy 
(Gersh BJ et al, Circulation 2011;124: e783-e831), ESC 
Guidelines for management of acute coronary syndromes 
in patients presenting without persistent ST-segment 
elevation (Eur Heart J 2011; 32: 2999-3054), ESC 
Guidelines on the management of cardiovascular diseases 
during pregnancy (Regitz-Zagrosek V et al, Eur Heart J 
2011;32: 3147-3197).  
